Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers.
Maubant S, Tahtouh T, Brisson A, Maire V, Némati F, Tesson B, Ye M, Rigaill G, Noizet M, Dumont A, Gentien D, Marty-Prouvost B, de Koning L, Mahmood SF, Decaudin D, Cruzalegui F, Tucker GC, Roman-Roman S, Dubois T. Maubant S, et al. Among authors: maire v. Oncotarget. 2018 Apr 27;9(32):22586-22604. doi: 10.18632/oncotarget.25187. eCollection 2018 Apr 27. Oncotarget. 2018. PMID: 29854300 Free PMC article.
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T. Marty B, et al. Among authors: maire v. Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3. Breast Cancer Res. 2008. PMID: 19055754 Free PMC article.
Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierré A, Cruzalegui F, Depil S, Tucker GC, Dubois T. Maire V, et al. Cancer Res. 2013 Jan 15;73(2):813-23. doi: 10.1158/0008-5472.CAN-12-2633. Epub 2012 Nov 9. Cancer Res. 2013. PMID: 23144294
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierré A, Tucker GC, Dubois T. Maire V, et al. PLoS One. 2013 May 20;8(5):e63712. doi: 10.1371/journal.pone.0063712. Print 2013. PLoS One. 2013. PMID: 23700430 Free PMC article.
Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells.
Maubant S, Tesson B, Maire V, Ye M, Rigaill G, Gentien D, Cruzalegui F, Tucker GC, Roman-Roman S, Dubois T. Maubant S, et al. Among authors: maire v. PLoS One. 2015 Apr 7;10(4):e0122333. doi: 10.1371/journal.pone.0122333. eCollection 2015. PLoS One. 2015. PMID: 25848952 Free PMC article.
HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers.
El-Botty R, Vacher S, Mainguené J, Briaux A, Ibadioune S, Dahmani A, Montaudon E, Nemati F, Huguet L, Sourd L, Morriset L, Château-Joubert S, Dubois T, Maire V, Lidereau R, Rapinat A, Gentien D, Coussy F, Bièche I, Marangoni E. El-Botty R, et al. Among authors: maire v. Mol Oncol. 2023 Oct;17(10):2017-2028. doi: 10.1002/1878-0261.13412. Epub 2023 Mar 23. Mol Oncol. 2023. PMID: 36852691 Free PMC article.
47 results